Study finds hydroxychloroquine linked to higher death rate in Covid-19 patients
A study by the University Hospital of Zurich and Harvard Medical School finds the controversial antimalarial drugs, hydroxychloroquine and a similar drug chloroquine, show no benefit against Covid-19.
According to the studyExternal link published on Friday in the Lancet, hospitalised patients taking a regimen of the antimalarial drugs had a higher mortality rate. Patients treated with one of the drugs had a mortality rate of 11.1%, compared with 9.3% for a control sample.
The study, which was led by researchers at Harvard Medical School and the University Hospital of Zurich, evaluated 96,000 Covid-19 patients in 671 hospitals worldwide. About 15,000 of them were treated with one of the antimalarial drugs with or without antibiotics (macrolides such as azithromycin and clarithromycin) at the onset of the disease.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
The researchers also observed a four-fold increased risk of cardiac arrhythmia. Some 4-8% of patients treated with one of the antimalarial drugs experienced a new heart arrhythmia, compared to 0.3% for those who were not taking such treatment.
There is “no scientific evidence” of the effectiveness of hydroxychloroquine and chloroquine, said Frank Ruschitzka, head of the Department of Cardiology at the University Hospital of Zurich in a statementExternal link.
“Hydroxychloroquine and chloroquine should therefore no longer be used for Covid-19 before we have the results of further, currently ongoing randomised clinical studies.”
The antimalarial drugs have been surrounded by controversy after enthusiastic remarks by US President Donald Trump earlier this year that left some epidemiologists uneasy given the well-known risks of the drugs particularly for people with heart conditions.
Last week, President Trump indicated that he has been taking hydroxychloroquine as a preventative measure. The US Food and Drug Administration (FDA) granted the drug emergency use authorization earlier this year but European authorities have been less enthusiastic about the drug.
Some of the excitement and hope stemmed from some pre-clinical studies as well as anecdotal evidence that it improved patents’ recovery.
In Switzerland, 17 hospitals are currently participating in a World Health Organization (WHO) solidarity study to test the effectiveness of hydroxychloroquine.
More
More
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies’ balancing act between hope and scientific realities.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss hospitals lose up to CHF3 billion amid pandemic
This content was published on
Switzerland’s hospitals and clinics are facing a financial loss of between CHF1.7 billion and CHF2.9 billion due to the Covid-19 pandemic.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.